RCKT WACC - Weighted Average Cost of Capital
The WACC of Rocket Pharmaceuticals Inc (RCKT) is 7.3%.
| Range | Selected | |
| Cost of equity | 5.4% - 9.5% | 7.45% |
| Tax rate | 26.2% - 27.0% | 26.6% |
| Cost of debt | 5.0% - 5.0% | 5% |
| WACC | 5.3% - 9.3% | 7.3% |
| Category | Low | High |
| Long-term bond rate | 3.9% | 4.4% |
| Equity market risk premium | 4.6% | 5.6% |
| Adjusted beta | 0.33 | 0.83 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 5.4% | 9.5% |
| Tax rate | 26.2% | 27.0% |
| Debt/Equity ratio | 0.03 | 0.03 |
| Cost of debt | 5.0% | 5.0% |
| After-tax WACC | 5.3% | 9.3% |
| Selected WACC | 7.3% | |
| Debt/Equity | Unlevered | |||
| Peers | Company Name | ratio | Beta | beta |
| RCKT | Rocket Pharmaceuticals Inc | 0.03 | 1.94 | 1.91 |
| GOSS | Gossamer Bio Inc | 0.78 | 1.94 | 1.24 |
| HSTC | HST Global Inc | 0 | 0.79 | 0.79 |
| MRNA | Moderna Inc | 0.01 | 1.04 | 1.04 |
| NNBP | Nanobac Pharmaceuticals Inc | 16520.38 | 0 | 0 |
| VRTX | Vertex Pharmaceuticals Inc | 0 | 0.68 | 0.68 |
| Low | High | |
| Unlevered beta | 0.79 | 1.04 |
| Relevered beta | 0 | 0.75 |
| Adjusted relevered beta | 0.33 | 0.83 |
RCKT's CAPM model and how its cost of Equity is calculated
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for RCKT:
cost_of_equity (7.45%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.33) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.